STARPHARMA HOLDINGS LIMITED ADR
WKN: A2QE42 | ISIN: US8555631022 | Ticker-Symbol: PQ6ASiehe auch STARPHARMA HOLDINGS LIMITED
Frankfurt
22.12.25 | 08:12
2,000 Euro
+11,11 % +0,200
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | STARPHARMA HOLDINGS LIMITED: Change of Director's Interest Notice - C Maley | 4 | ASX | ||
| Mi | STARPHARMA HOLDINGS LIMITED: Notification regarding unquoted securities - SPL | 2 | ASX | ||
| 14.11. | STARPHARMA HOLDINGS LIMITED: Results of 2025 Annual General Meeting | 1 | ASX | ||
| 14.11. | STARPHARMA HOLDINGS LIMITED: AGM Chair address and CEO presentation | 3 | ASX | ||
| STARPHARMA HOLDINGS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 27.10. | STARPHARMA HOLDINGS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 4 | ASX | ||
| 22.10. | STARPHARMA HOLDINGS LIMITED: Upfront payment of USD $5.5 million received from Genentech | 12 | ASX | ||
| 21.10. | STARPHARMA HOLDINGS LIMITED: Australian Microcap Investment Conference presentation | 1 | ASX | ||
| 21.10. | STARPHARMA HOLDINGS LIMITED: Change of Director's Interest Notice - R Thomas | 1 | ASX | ||
| 13.10. | STARPHARMA HOLDINGS LIMITED: Notice of 2025 Annual General Meeting/Proxy Form | - | ASX | ||
| 06.10. | STARPHARMA HOLDINGS LIMITED: Change of Director's Interest Notice - C Maley | 2 | ASX | ||
| 06.10. | STARPHARMA HOLDINGS LIMITED: Notification of cessation of securities - SPL | 2 | ASX | ||
| 30.09. | Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset | 5 | smallcaps.com.au | ||
| 30.09. | Starpharma and Radiopharm Theranostics Partner on Novel Radiotherapy Asset | 1 | Finance News Network | ||
| 30.09. | STARPHARMA HOLDINGS LIMITED: RAD: Radiopharm Theranostics Partners with SPL on Research | - | ASX | ||
| 30.09. | STARPHARMA HOLDINGS LIMITED: Research and Option Agreement with Radiopharm Theranostics | - | ASX | ||
| 22.09. | Starpharma Announces a Collaboration and License Agreement with Genentech | 239 | GlobeNewswire (Europe) | MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license... ► Artikel lesen | |
| 22.09. | Health Check: Starpharma revs up on Big Pharma deal worth up to $855m | 4 | Stockhead | ||
| 22.09. | Lunch Wrap: Newmont jumps on $900m asset sale, Starpharma soars | 30 | Stockhead | ||
| 22.09. | Starpharma Partners with Genentech to Develop Innovative Cancer Therapies Using DEP Technology | 11 | smallcaps.com.au | ||
| 22.09. | Top 10 at 11: ASX starts week on the up as Starpharma shines on Big Pharma deal | 1 | Stockhead |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,396 | -4,82 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| QIAGEN | 39,120 | +1,76 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,11 | -0,30 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,750 | +0,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| BIONTECH | 79,05 | 0,00 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| JYONG BIOTECH | 6,330 | +99,37 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,495 | +5,39 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| EVOTEC | 5,226 | +1,59 % | Eilmeldung am Abend: EVOTEC SE - jetzt wird's brisant! | ||
| IMMUNOME | 22,000 | +2,80 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| OLEMA PHARMACEUTICALS | 28,550 | +2,59 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 64,30 | -0,99 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 53,30 | +4,24 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| BEAM THERAPEUTICS | 28,140 | +5,91 % | BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy | ||
| SUMMIT THERAPEUTICS | 18,015 | +1,09 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| KYMERA THERAPEUTICS | 84,96 | +1,15 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital |
Das Unternehmen STARPHARMA HOLDINGS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,200 (+11,11 %) liegt der Kurs bei 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STARPHARMA HOLDINGS LIMITED ADR finden Sie auf Wallstreet Online.